Evotec AG has advanced a compound in its strategic alliance with Boehringer Ingelheim into Phase I clinical studies. Evotec will receive a $2.5 million milestone payment as a result. The compound was discovered and optimized within the alliance and is being developed as a treatment for neuropathic pain. The alliance has involved multiple high priority targets across key therapeutic areas and was recently expanded for four additional years to include oncology. To date, it has resulted in eight...